Ymatzu RGF, Querevalú MWA, George AF, Leal GLO, Jaramillo SEA, Pizaña DA

Language: Spanish
References: 12
Page: 233-237
PDF size: 1766.75 Kb.

ABSTRACT

Plasmacytoma is a plasma cell tumor and can occur anywhere in the body. It is a malignant neoplasm and is considered an intermediate phase between monoclonal gammopathy of undetermined significance and multiple myeloma. The case of a patient with upper motor neuron and complete spinal cord syndrome is presented. The definitive diagnosis was extramedullary plasmacytoma in a biopsy of the iliac crest and thoracic vertebrae. The treatment was approached in a multidisciplinary manner between intensive care, neurosurgery, hematology, algology and psychology. Treatment can be carried out with chemotherapy, radiotherapy and/or surgery, with radiotherapy being the mainstay of treatment.

REFERENCES

1. Meyer HJ, Ullrich S, Hamerla G, Surov A. Extramedullaryplasmacytoma. Rofo. 2018;190(11):1006-1009.

2. International Myeloma Working Group. Criteria for theclassification of monoclonal gammopathies, multiple myelomaand related disorders: a report of the International MyelomaWorking Group. Br J Haematol. 2003;121(5):749-757.

3. Dattolo P, Allinovi M, Michelassi S, Pizzarelli F. Multiplesolitary plasmacytoma with multifocal bone involvement.First clinical case report in a uraemic patient. BMJ Case Rep.2013;2013:bcr2013009157.

4. Dores GM, Landgren O, McGlynn KA, Curtis RE, LinetMS, Devesa SS. Plasmacytoma of bone, extramedullaryplasmacytoma, and multiple myeloma: incidence and survival inthe United States, 1992-2004. Br J Haematol. 2009;144(1):86-94.

5. Lombardo EM, Maito FLDM, Heitz C. Solitary plasmacytomaof the jaws: therapeutical considerations and prognosis basedon a case reports systematic survey. Braz J Otorhinolaryngol.2018;84(6):790-798.

6. Low SF, Mohd Tap NH, Kew TY, Ngiu CS, Sridharan R. Nonsecretory multiple myeloma with extensive extramedullaryplasmacytoma: a diagnostic dilemma. Iran J Radiol.2015;12(3):e11760.

7. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R.Solitary plasmacytoma of bone and asymptomatic multiplemyeloma. Blood. 2000;96(6):2037-2044.

8. Aalto Y, Nordling S, Kivioja AH, Karaharju E, Elomaa I, KnuutilaS. Among numerous DNA copy number changes, losses ofchromosome 13 are highly recurrent in plasmacytoma. GenesChromosomes Cancer. 1999;25(2):104-107.

9. Wang L, Ren NJ, Cai H, Cheng HF, Zhang HL, Peng XB, et al.Solitary plasmacytoma of the occipital bone: a case report. J IntMed Res. 2020;48(8):300060520914817.

10. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY,et al. Diagnosis, treatment, and response assessment in solitaryplasmacytoma: updated recommendations from a EuropeanExpert Panel. J Hematol Oncol. 2018;11(1):10.

11. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X,Siegel D, et al. Carfilzomib, dexamethasone, and daratumumabversus carfilzomib and dexamethasone for patients with relapsedor refractory multiple myeloma (CANDOR): results from arandomised, multicentre, open label, phase 3 study. Lancet.2020;396:186-197.

12. Singh D, Wadhwa J, Kumar L, Raina V, Agarwal A, KochupillaiV. POEMS syndrome: experience with fourteen cases. LeukLymphoma. 2003;44(10):1749-1752.